| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Pernille Fog Svendsen, Lisbeth Nilas, Sten Madsbad, Jens Juul Hols. Incretin hormone secretion in women with polycystic ovary syndrome: roles of obesity, insulin sensitivity, and treatment with metformin. Metabolism: clinical and experimental. vol 58. issue 5. 2009-05-04. PMID:19375579. |
plasma concentrations of gip and glp-1 were determined frequently during a 75-g glucose tolerance test, and insulin sensitivity was evaluated by the euglycemic hyperinsulinemic clamp. |
2009-05-04 |
2023-08-12 |
human |
| T Edholm, K Cejvan, S M Abdel-Halim, S Efendic, P T Schmidt, P M Hellströ. The incretin hormones GIP and GLP-1 in diabetic rats: effects on insulin secretion and small bowel motility. Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society. vol 21. issue 3. 2009-05-01. PMID:19126188. |
the incretin hormones gip and glp-1 in diabetic rats: effects on insulin secretion and small bowel motility. |
2009-05-01 |
2023-08-12 |
rat |
| T Edholm, K Cejvan, S M Abdel-Halim, S Efendic, P T Schmidt, P M Hellströ. The incretin hormones GIP and GLP-1 in diabetic rats: effects on insulin secretion and small bowel motility. Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society. vol 21. issue 3. 2009-05-01. PMID:19126188. |
the aim of this study was to investigate if altered responsiveness to glucose-dependent insulinotropic peptide (gip) and glucagon-like peptide-1 (glp-1) as regards insulin release and small bowel motility could bring further clarity to the pathophysiology of diabetes in the goto-kakizaki (gk) rat. |
2009-05-01 |
2023-08-12 |
rat |
| T Edholm, K Cejvan, S M Abdel-Halim, S Efendic, P T Schmidt, P M Hellströ. The incretin hormones GIP and GLP-1 in diabetic rats: effects on insulin secretion and small bowel motility. Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society. vol 21. issue 3. 2009-05-01. PMID:19126188. |
glucose-dependent insulinotropic peptide (10 nmol l(-1)) or glp-1 (10 nmol l(-1)) were added to the medium and perfusate was collected and analysed for insulin. |
2009-05-01 |
2023-08-12 |
rat |
| T Edholm, K Cejvan, S M Abdel-Halim, S Efendic, P T Schmidt, P M Hellströ. The incretin hormones GIP and GLP-1 in diabetic rats: effects on insulin secretion and small bowel motility. Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society. vol 21. issue 3. 2009-05-01. PMID:19126188. |
under euglycemia, gip and glp-1 stimulated the initial insulin response by 10-fold in gk rats (p < 0.05). |
2009-05-01 |
2023-08-12 |
rat |
| T Edholm, K Cejvan, S M Abdel-Halim, S Efendic, P T Schmidt, P M Hellströ. The incretin hormones GIP and GLP-1 in diabetic rats: effects on insulin secretion and small bowel motility. Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society. vol 21. issue 3. 2009-05-01. PMID:19126188. |
at later hyperglycemia, the insulin response to gip and glp-1 was blunted to about one-third compared with controls (p < 0.05). |
2009-05-01 |
2023-08-12 |
rat |
| T Edholm, K Cejvan, S M Abdel-Halim, S Efendic, P T Schmidt, P M Hellströ. The incretin hormones GIP and GLP-1 in diabetic rats: effects on insulin secretion and small bowel motility. Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society. vol 21. issue 3. 2009-05-01. PMID:19126188. |
the initially high, but later low insulin responsiveness to stimulation with gip and glp-1 along with inhibition of small bowel motility in the gk rat indicates a preserved incretin response on motility in diabetes type 2. |
2009-05-01 |
2023-08-12 |
rat |
| Vandana S Raman, Rubina A Heptull. New potential adjuncts to treatment of children with type 1 diabetes mellitus. Pediatric research. vol 65. issue 4. 2009-04-30. PMID:19092720. |
further studies with the use of amylin analogs and long-acting glp-1 agonists as congeners with insulin in t1dm are indicated in children. |
2009-04-30 |
2023-08-12 |
human |
| Feruze Yilmaz Enç, Tunç Ones, H Levent Akin, Fuat Dede, H Turgut Turoğlu, Gözde Ulfer, Nural Bekiroğlu, Goncagül Haklar, Jens F Rehfeld, Jens J Holst, Nefise B Ulusoy, Neşe Imeryü. Orlistat accelerates gastric emptying and attenuates GIP release in healthy subjects. American journal of physiology. Gastrointestinal and liver physiology. vol 296. issue 3. 2009-04-28. PMID:19109408. |
orlistat significantly attenuated the secretion of glucose-dependent insulinotropic polypeptide (gip) but did not alter the plasma responses of cholecystokinin (cck), glucagon-like peptide-1 (glp-1), pancreatic polypeptide (pp), and insulin. |
2009-04-28 |
2023-08-12 |
human |
| Martha M Funnel. The therapeutic role of incretin mimetics and DPP-4 inhibitors. The Diabetes educator. vol 35 Suppl 1. 2009-04-27. PMID:19218562. |
gastric inhibitory peptide (gip) and glucagon-like peptide-1 (glp-1) stimulate the secretion of insulin when blood glucose levels are elevated and inhibit the postprandial release of glucagon. |
2009-04-27 |
2023-08-12 |
Not clear |
| Angela Bulotta, Loredana Farilla, Hongxiang Hui, Riccardo Perfett. The role of GLP-1 in the regulation of islet cell mass. Cell biochemistry and biophysics. vol 40. issue 3 Suppl. 2009-04-24. PMID:15289644. |
the aim of this article is to review those reports that have emphasized the role of glp-1 as a regulator of islet cell mass as well as its insulin secretory action. |
2009-04-24 |
2023-08-12 |
human |
| Yukihiro Fujita, Rhonda D Wideman, Madeleine Speck, Ali Asadi, David S King, Travis D Webber, Masakazu Haneda, Timothy J Kieffe. Incretin release from gut is acutely enhanced by sugar but not by sweeteners in vivo. American journal of physiology. Endocrinology and metabolism. vol 296. issue 3. 2009-04-20. PMID:19106249. |
glucose-dependent insulinotropic polypeptide (gip) and glucagon-like peptide-1 (glp-1) are released during meals from endocrine cells located in the gut mucosa and stimulate insulin secretion from pancreatic beta-cells in a glucose-dependent manner. |
2009-04-20 |
2023-08-12 |
rat |
| Derek D Mafong, Robert R Henr. The role of incretins in cardiovascular control. Current hypertension reports. vol 11. issue 1. 2009-04-10. PMID:19146796. |
in patients with t2dm, glp-1 infusion has been shown to improve endothelial function, irrespective of changes in insulin sensitivity. |
2009-04-10 |
2023-08-12 |
human |
| Feng Qian, Neil Mathias, Paul Moench, Cecilia Chi, Sridhar Desikan, Munir Hussain, Ronald L Smit. Pulmonary delivery of a GLP-1 receptor agonist, BMS-686117. International journal of pharmaceutics. vol 366. issue 1-2. 2009-04-07. PMID:19027057. |
in recent years, much attention has centered on pulmonary peptide delivery of peptide drugs such as insulin and glp-1 mimetic peptides in the treatment of type ii diabetes. |
2009-04-07 |
2023-08-12 |
rat |
| Filip K Knop, Tina Vilsbøll, Jens J Hols. Incretin-based therapy of type 2 diabetes mellitus. Current protein & peptide science. vol 10. issue 1. 2009-04-07. PMID:19275672. |
therefore, the actions of glp-1 and gip, which include potentation of meal-induced insulin secretion and trophic effects on the beta-cell, have attracted a lot of interest. |
2009-04-07 |
2023-08-12 |
Not clear |
| F M Gribbl. RD Lawrence Lecture 2008: Targeting GLP-1 release as a potential strategy for the therapy of Type 2 diabetes. Diabetic medicine : a journal of the British Diabetic Association. vol 25. issue 8. 2009-04-02. PMID:18959599. |
glucagon-like peptide-1 (glp-1) and glucose-dependent insulinotropic polypeptide (gip) are gastrointestinal hormones that play an important role in stimulating postprandial insulin release from pancreatic beta-cells. |
2009-04-02 |
2023-08-12 |
Not clear |
| Rajesh Gupta, Sameer S Walunj, Ranjeet K Tokala, Kishore V L Parsa, Santosh Kumar Singh, Manojit Pa. Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Current drug targets. vol 10. issue 1. 2009-03-27. PMID:19149538. |
inhibition of plasma dpp iv enzyme leads to enhanced endogenous glp-1 and gip activity, which ultimately results in the potentiation of insulin secretion by pancreatic beta-cells and subsequent lowering of blood glucose levels, hba[1(c)], glucagon secretion and liver glucose production. |
2009-03-27 |
2023-08-12 |
Not clear |
| Julio E Ayala, Deanna P Bracy, Freyja D James, Brianna M Julien, David H Wasserman, Daniel J Drucke. The glucagon-like peptide-1 receptor regulates endogenous glucose production and muscle glucose uptake independent of its incretin action. Endocrinology. vol 150. issue 3. 2009-03-24. PMID:19008308. |
glucagon-like peptide-1 (glp-1) diminishes postmeal glucose excursions by enhancing insulin secretion via activation of the beta-cell glp-1 receptor (glp1r). |
2009-03-24 |
2023-08-12 |
mouse |
| C Beglinger, B Poller, E Arbit, C Ganzoni, S Gass, I Gomez-Orellana, J Drew. Pharmacokinetics and pharmacodynamic effects of oral GLP-1 and PYY3-36: a proof-of-concept study in healthy subjects. Clinical pharmacology and therapeutics. vol 84. issue 4. 2009-03-24. PMID:19238651. |
in healthy male volunteers, (i) oral administration of either of the peptides induced a rapid and dose-dependent increase in plasma drug concentrations; (ii) oral administration of glp-1 induced a potent effect on insulin release; and (iii) both peptides suppressed ghrelin secretion. |
2009-03-24 |
2023-08-12 |
human |
| Atsuo Tahara, Akiko Matsuyama-Yokono, Ryosuke Nakano, Yuka Someya, Masahiko Hayakawa, Masayuki Shibasak. Evaluation of the antidiabetic effects of dipeptidyl peptidase-IV inhibitor ASP8497 in streptozotocin-nicotinamide-induced mildly diabetic mice. Pharmacology. vol 83. issue 3. 2009-03-23. PMID:19176982. |
a single oral administration of asp8497 (0.3-3 mg/kg) significantly improved glucose tolerance by increasing plasma insulin and glp-1 levels during the oral glucose or liquid meal tolerance tests. |
2009-03-23 |
2023-08-12 |
mouse |